ABDX Stock Overview
Engages in the development, manufacture, and distribution of diagnostic devices in the United Kingdom, the United States, Canada, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Abingdon Health Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.11 |
52 Week High | UK£0.14 |
52 Week Low | UK£0.065 |
Beta | 0.13 |
11 Month Change | -1.79% |
3 Month Change | 4.76% |
1 Year Change | 2.33% |
33 Year Change | -74.42% |
5 Year Change | n/a |
Change since IPO | -89.57% |
Recent News & Updates
Recent updates
Shareholder Returns
ABDX | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | -2.2% | 0.1% | -1.2% |
1Y | 2.3% | -3.6% | 4.4% |
Return vs Industry: ABDX exceeded the UK Medical Equipment industry which returned -2.3% over the past year.
Return vs Market: ABDX underperformed the UK Market which returned 5.4% over the past year.
Price Volatility
ABDX volatility | |
---|---|
ABDX Average Weekly Movement | 6.2% |
Medical Equipment Industry Average Movement | 6.1% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.7% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ABDX has not had significant price volatility in the past 3 months.
Volatility Over Time: ABDX's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 84 | Chris Henry Yates | www.abingdonhealth.com |
Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices in the United Kingdom, the United States, Canada, Europe, and internationally. The company provides Abingdon Simply Test, a range of self-tests in the field of fertility, health and well-being, infectious diseases, and drug testing; PCRD and PCRD FLEX, are nucleic acid lateral flow tests, which are used for rapid readouts post isothermal amplification; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2, as well as plant health tests; and nucleic acid lateral flow immunoassays. It also offers AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader; and Salistick, a rapid saliva-based pregnancy test.
Abingdon Health Plc Fundamentals Summary
ABDX fundamental statistics | |
---|---|
Market cap | UK£33.64m |
Earnings (TTM) | -UK£2.23m |
Revenue (TTM) | UK£5.34m |
6.4x
P/S Ratio-15.4x
P/E RatioIs ABDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABDX income statement (TTM) | |
---|---|
Revenue | UK£5.34m |
Cost of Revenue | UK£2.28m |
Gross Profit | UK£3.07m |
Other Expenses | UK£5.30m |
Earnings | -UK£2.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0071 |
Gross Margin | 57.35% |
Net Profit Margin | -41.82% |
Debt/Equity Ratio | 39.7% |
How did ABDX perform over the long term?
See historical performance and comparison